Lisa Walter
Stock Analyst at RBC Capital
(2.81)
# 1,569
Out of 5,090 analysts
11
Total ratings
66.67%
Success rate
20.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $8.65 | +84.97% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $10.70 | +199.07% | 2 | Nov 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $41 → $45 | $32.02 | +40.54% | 2 | Nov 6, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $28 → $39 | $17.74 | +119.84% | 2 | Nov 6, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $569 → $587 | $489.31 | +19.96% | 2 | Oct 30, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $3 → $4 | $4.26 | -6.10% | 1 | Oct 28, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $17 → $19 | $23.63 | -19.59% | 1 | Aug 1, 2025 |
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $8.65
Upside: +84.97%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $10.70
Upside: +199.07%
Viridian Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $41 → $45
Current: $32.02
Upside: +40.54%
EyePoint Pharmaceuticals
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $17.74
Upside: +119.84%
United Therapeutics
Oct 30, 2025
Maintains: Outperform
Price Target: $569 → $587
Current: $489.31
Upside: +19.96%
Adverum Biotechnologies
Oct 28, 2025
Maintains: Sector Perform
Price Target: $3 → $4
Current: $4.26
Upside: -6.10%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Sector Perform
Price Target: $17 → $19
Current: $23.63
Upside: -19.59%